Presenter Disclosure Information
|
|
- Shannon Golden
- 5 years ago
- Views:
Transcription
1 12:45 1:3 pm Improving Outcomes in COPD SPEAKER Michael Campos, MD Presenter Disclosure Information The following relationships exist related to this presentation: Michael Campos, MD: No financial relationships to disclose. Off-Label/Investigational Discussion In accordance with pmicme policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. COPD knowledge: Why Is it Important in Primary Care? COPD PATIENT SURVEY Physician primarily responsible for their COPD care: General practitioner 62% Pulmonologist 3% COPD PHYSICIAN SURVEY % of COPD patients in their practice: Primary care 12% Pulmonologists 3% % Aware of any professional guidelines for the and management of COPD: Primary care 54% Pulmonologists 94% Barr RG et al. Am J Med. 25 Dec;118(12):1415 Discuss epidemiology: Improving Review pathophysiology Discuss comorbidities and Identify prognostic factors Review pharmacologic and nonpharmacologic Implement management strategies for Discuss epidemiology: Improving Review pathophysiology Discuss comorbidities and Identify prognostic factors Review pharmacologic and nonpharmacologic Implement management strategies for The Cost of COPD - 21 Total burden of COPDattributable costs: $36 billion Total national medical costs attributable to COPD: $32.1 billion Total absenteeism costs: $3.9 billion (an estimated 16.4 million lost work days) Payers: 18% private insurance 51% Medicare 25% Medicaid National medical costs are projected to increase from $32.1 billion in 21 to $49. billion in 22 Ford ES et al. CHEST 215; 147(1) : 31-45
2 Overall Health Care Costs Are Higher in Patients With COPD Mean Health Care Cost per Person (US dollars) COPD cohort (n=837) Other health-care-related costs* Outpatient costs Hospitalization costs Comparison cohort (n=837) *Included emergency room visits, physician visits, and pharmacy costs. Each comparator was based on the mean of 3 controls from a data set including 25,11 patients. Menzin J et al. Respir Med. 28;12: COPD, US 27-29, MEN 12 % of US men population COPD Prevalence increases with age Age Groups NCHS Data Brief No. 63 June 211 CDC/NCHS, Health Data Interactive and National Health Interview Survey If... Spirometry Is Essential for Diagnosing COPD Chronic symptoms = cough, sputum, and/or shortness of breath And... Exposure to risk factors = tobacco, occupational irritants, and/or indoor/outdoor pollution Then... Spirometry* to confirm COPD FEV 1 /FVC <.7 FEV 1 determines staging ACP, ACCP, ATS, and ERS Clinical Practice Guideline Recommendation 1: Spirometry should be obtained to diagnose airflow obstruction in patients with respiratory symptoms (Grade: strong recommendation) Spirometry should not be used to screen for airflow obstruction in individuals without respiratory symptoms (Grade: strong recommendation) Spirometry should not be used to monitor disease status or response to treatment after COPD. *Additional testing: chest x-ray, echocardiogram, arterial blood gas, sputum analysis, computed tomography (CT) scan. Global Initiative for Chronic Obstructive Lung Disease. Ann Int Med 211 (155)3: Onset Triggers Differentiating COPD and Asthma Different Diseases Asthma Early in life (often childhood) Allergens COPD Mid-life Cigarette smoke, occupational pollutants Symptoms Variable Slowly progressive Airflow limitation Largely reversible Partially reversible Clinical features Episodic wheeze, chest Chronic dyspnea, cough, sputum, tightness, cough, dyspnea wheeze Inflammatory Pathology Other PFT features Primarily eosinophils (lung, peripheral blood, sputum) Airway remodeling; no lung destruction Normal D L CO Primarily neutrophils Airway remodeling and lung destruction Reduced D L CO, static hyperinflation Imaging No emphysema Emphysema Discuss epidemiology: Improving Review pathophysiology Discuss comorbidities and Identify prognostic factors Review pharmacologic and nonpharmacologic Implement management strategies for Global Initiative for Chronic Obstructive Lung Disease. Global strategy for, management, and prevention of chronic obstructive pulmonary disease. Updated
3 Lung Function Decline in COPD Expiratory Airflow Limitation Air Trapping 1 8 Non-smoker Hyperinflation Decreased Exercise Capacity Reduced Activity FEV 1 (%) Symptoms Disability Death Susceptible smoker The vicious cycle of COPD Dyspnea Physical Deconditioning Age (years) Fletcher C, Peto R. Br Med J. 1977;1: Poor Health-Related Quality of Life Co-morbidity and prognosis Discuss epidemiology: Improving Review pathophysiology Discuss comorbidities and Identify prognostic factors Review pharmacologic and nonpharmacologic Implement management strategies for Death within 5 years Predict death within 5 yrs by modified GOLD category and the presence of no ( ), one ( ), two ( ) or three ( ) comorbid diseases (diabetes, hypertension or cardiovascular disease). Mannino et al, ERJ 28 COPD: an independent risk factor for CV Disease Fibrinogen and COPD For each 1% reduction of FEV 1, cardiovascular mortality increases by 28% Presence of COPD increases the odds of having CVD by 2-3 times which was independent of other risk factors A 2.27-fold increased risk of MI was seen 1 to 5 days after COPD exacerbation Associated with reduced lung function and disease progression independent of smoking status. Dahl M et al. Am J Respir Crit Care Med 21; 164 (6): Predict future risk of moderate and severe exacerbations and hospitalizations from COPD Groenewegen KH et al. Chest 28; 133 (2): 35-7 Engstrom G et al. Thorax 29; 64 (3): Not easily modifiable with medications Likely to be the first COPD biomarker presented to the FDA for qualification in the drug approval process. Rosenberg & Kalhan. Translac Res 212;159: Finkelstein J. Chronic. Int. J COPD 29; 4: Soriano J., et al. Chest 21; 137: Donaldson G. et al. Chest 21; 137(5):
4 Heterogeneity in Disease Progression: FEV 1 Decline FEV 1 (%) Symptoms Disability Death Smoker Age (years) Non-smoker Fletcher C, Peto R. Br Med J. 1977;1: Discuss epidemiology: Improving Review pathophysiology Discuss comorbidities and Identify prognostic factors Review pharmacologic and nonpharmacologic Implement management strategies for Recommendations for Evaluating Patients with COPD Discuss epidemiology: Improving Review pathophysiology Discuss comorbidities and Identify prognostic factors Review pharmacologic and nonpharmacologic Implement management strategies for 1. Spirometry before and after bronchodilator 2. Imaging (CXR) 3. Examination of the sputum 4. Comorbidity assessment 5. Evaluate need for oxygen 6. Determine exacerbation phenotype 7. Functional status 8. Composite score 9. Test for AAT Deficiency Alpha-1 Antitrypsin Deficiency 1-2% of all COPD and unexplained liver cirrhosis Smoking is the most important factor for an Alpha to develop COPD Recommendations to test all COPD patients regardless of smoking, age, race, emphysema pattern AAT levels, phenotype or genotype Genotypes: MM: normal MZ: carrier ZZ: severely deficient Am J Resp Crit Care Med 23; 168(818-9) Pharmacologic Options for COPD Short-acting bronchodilators Anticolinergics (SAAC) Beta-agonists (SABA) Long acting bronchodilators Anticolinergics or long-acting muscarinic antagonists (LAMA) Beta-agonists (LABA) Inhaled Corticosteroids (ICS) PDE-4 inhibitors Inhaled bronchodilators are preferred over oral Long-acting bronchodilators are preferred over short-acting ICS never as monotherapy. Add to high risk patients with long-acting BD No chronic oral steroids
5 NEW LAMAs Tiotropium Glycopyrronium Umeclidinium Aclidinium TD-428 CHF 547 QAT37 BEA-218BR Trospium Dexpirronium AZD8683 PF or PF New LABAs Salmeterol Formoterol Indacaterol Vilanterol Olodaterol Abediterol (LAS-1977) AZD3199 PF LABA + ICS: Improvement in lung function LABA + ICS: Improvement in lung function Budesonide/formoterol FEV 1 (ml) PLA SAL 5 FLU/SAL 25/5 (17%) 2 15 (9%) 1 5 (1%) -5 Endpoint (last evaluable FEV 1) Time (weeks) * Mean FEV 1 % of baseline Formoterol Budesonide Placebo Months since randomization Hanania et al. Chest. 23;124: Calverley PM, et al. Eur Respir J. 23;22: LABA + ICS: Improvement in dyspnea LABA + ICS: Decrease exacerbations 2 Mean TDI focal score Placebo SAL FP 5 µg FSC 5/5 µg Mean exacerbations per year Time (weeks) P SAL FP FSC End point Placebo Formoterol Budesonide Formoterol + Budesonide FSC=fluticasone propionate + salmeterol combination. Mahler DA, et al. Am J Respir Crit Care Med. 22;166: Szafranski W, et al. Eur Respir J. 23;21:74-81.
6 LABA + ICS formulations LABA + LAMA: Improvement in lung function Salmeterol + Fluticasone Formoterol + Budesonide (Formoterol + mometasone) Vilanterol + Fluticasone Formoterol + ciclesonide Indacaterol + mometasone Indacaterol + QAE-397 GS-4242 (novel mutual prodrug of salmeterol and desisobutrylciclesonide) FEV 1 (L) AM 3 PM 9 PM 3 AM 9 AM Time (hours) Tiotropium qd + formoterol qd Tiotropium qd + formoterol bid Tiotropium qd + placebo bid 24-hour base van Noord JA et al. Chest 26;129:59-17 LAMA + LABA Patients May Respond to Long-term Bronchodilator Therapy, Regardless of Initial Reversibility Status Umeclidinium/ vilanterol Olodaterol/ tiotropium Indacaterol/ glycopyrronium Formoterol/aclidinium Formoterol/glycopyrrolate FEV 1 (liters) Day 1 Day Placebo Tiotropium 1.4 Placebo Tiotropium 1.3 FEV 1 (liters) * * Time (minutes) Responders n=921. *P<.1 vs placebo at all time points following drug administration. Tashkin D, Kesten S. Chest. 23;123: Time (minutes) Poor Responders Long-Term Oxygen Therapy Pulmonary Rehabilitation Oxygen therapy decreases mortality in patients that qualify At least > 16h a day Indications: po2 < 55 mmhg at rest po2 < 59 if PHTN, cor pulmonale or polycythemia (Htc > 55%) Desaturation on exertion ACP, ACCP, ATS, and ERS recommend that clinicians should prescribe continuous oxygen therapy in patients with COPD who have severe resting hypoxemia (PaO2 55 mm Hg or SpO2 88%) (Grade: strong recommendation, moderate-quality evidence). A comprehensive PR program includes: exercise training optimal medical management oxygen supplementation (when required) psychosocial support nutrition counseling Education To be effective at least eight weeks is mandatory; the longer the duration, the better the results Ann Int Med 211 (155)3:
7 Benefits of Pulmonary Rehabilitation Lung Volume Reduction Surgery Improves Exercise performance Health-related QOL Self-management Psychosocial states Participation in daily life Self-efficacy Survival Reduced: Secondary comorbiditie (i.e. cardiac dysfunction) Dyspnea Severity of symptoms Health care costs Exacerbations/hospitaliza tions Psychological dysfunction For patients with poor functional capacity after rehabilitation and upper lobe emphysema Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest. 27 May;131(5 Suppl):4S-42S Epidemiology: Improving Understanding pathophysiology Understanding comorbidities and Understanding prognostic factors Understanding pharmacologic and non-pharmacologic Management of acute exacerbations and preventing When to give antibiotics?: Assessing sputum color More reliable when assess in the lab compared with patient verbal report (correlation with cultures and inflammatory markers) One small trial did not show difference in therapeutic failure (9% vs 1%) Non-invasive positive pressure ventilation Discharge Criteria 14 RCT show benefit of NPPV as first line intervention as an adjunct therapy to usual medical care in all suitable patients for the management of respiratory failure secondary to an acute exacerbation of COPD Improves gas exchange Reduces hospital mortality Decreases intubation rate Decreases hospital stay Indications: Respiratory acidosis Severe dyspnea w respiratory fatigue Ram FS et al. Cochrane Database Syst Rev 24;(3):CD414 Able to use long-acting bronchodilators Require use of short-acting BD no more frequently than every 4 hours Able to walk across room Clinical stability for 12-24h Patient or caregiver fully understands correct use of medications F/U and home care arrangements completed Patient or family confident that patient can manage succesfully at home
8 COPD: Readmissions and Medicare Approximately 2% of patients hospitalized for COPD exacerbations in the United States will be readmitted within 3 days. The Centers for Medicare and Medicaid Services has recently proposed to revise the Hospital Readmissions Reduction Program to financially penalize hospitals with high all-cause 3-day rehospitalization rates after a hospitalization for COPD exacerbation on or after October 1, 214 Reported Predictors for 3-d COPD Depression Socioeconomic status Heart disease Male sex Nursing home residence Age Cor pulmonale lower quality of life Hypoproteinemia elevated PCO2 Anemia Prior hospitalization longer hospital length of stay higher number of comorbidities need for long-term oxygen treatment worse lung function marital status serum Mg and CRP Poor follow-up Ohar JA. Ann Am Thorac Soc 215: 12 (9): Pulmonary Rehabilitation After COPD Exacerbations Preventing exacerbations in COPD: Azithromycin Immediately or up to three weeks after initiation of exacerbation treatment. Cochrane review of 6 studies (241 patients): Decrease in : OR.13 (95% CI.4 to.35) with a NNT of 3 (95% CI 2 to 4) f/u 8 months Decrease in mortality: OR.29 (95% CI.1 to.84) a NNT of 6 (95% CI 5 to 3) f/u 26 months Improved HRQOL: SGRQ difference of 11 units; CRQ difference of 1.8 units 1 year RCT of 1142 subjects: 57 azithromycin 25 mg daily 572 placebo Funded by NIH Azithromycin: Decreased frequency of exacerbations (1.48 vs 1.83 per patient-year). HR for acute exacerbation per patient-year:.73 Puhan M et al. Cochrane Database Syst Rev. 29 Jan 21 Improved quality of life Decrease colonization with selected respiratory pathogens, but also an increase in colonization with macrolide-resistant organisms More hearing decrements (25% vs. 2%, P=.4). Albert R et al. NEJM 211;365: End-of-Life Issues and COPD Survey of 376 patients. 14.6% reported having end-of-life discussions. These subjects were: more likely to rate their quality of care as the best imaginable (OR, 2.7;95% CI, ) a More likely to be very satisfied with their medical care (OR, 1.98; 95% CI, ) Perceptions about COPD among Primary Care A survey by Yawn et al. among 284 PCPs and NPs/PAs about COPD in primary care revealed that: 78% believe COPD was a disease of men 61% said that COPD usually started age 6 Only 15% believe that COPD treatments are useful in relieving symptoms Only 3% thought pulmonary rehab was beneficial Leung et al. CHEST 212; 142(1): Yawn et al, Int Journal COPD. 28; 3(2):
COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationShaping a Dynamic Future in Respiratory Practice. #DFResp
Shaping a Dynamic Future in Respiratory Practice #DFResp www.dynamicfuture.co.uk Inhaled Therapy in COPD: Past, Present and Future Richard Russell Chest Physician West Hampshire Integrated Respiratory
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationLecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)
Lecture Notes Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Objectives Define COPD Estimate incidence of COPD in the US Define factors associated with onset of COPD Describe the clinical features
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationCOPD UPDATE ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center
COPD UPDATE 2012 ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center Definition of COPD COPD is a preventable and treatable disease with some significant extra pulmonary effects that
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationObjectives. Advances in Managing COPD Patients
4:45 5:30pm Advances in Managing Patients SPEAKER Nicola Hanania, MD, FCCP, FRCP, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Nicola Hanania, MD,
More informationUpdate in Pulmonology Update in Medicine and Primary Care November 11, 2017
Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Denitza P. Blagev, MD Pulmonary & Critical Care Medicine Director, Schmidt Chest Clinic Director, Lung Cancer Screening Program
More informationOptimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center
Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center dtaylor@ochsner.org Observations from Yesterday EPIC is epidemic No EMR No Way!!! Accountability/Benchmarking
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationCOPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic
COPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic Learning Objectives Know the adverse effects of COPD exacerbations Know mainstays
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationCOPD Update. Muhammad Talha Khan MD. COPD Exacerbations. COPD Clinical Importance. COPD Pathophysiology. Overview/Objectives
Overview/Objectives COPD Update Muhammad Talha Khan MD Pulmonologist St Croix Regional Medical Center, St Croix Falls, WI. Overview of COPD and disease impact Classification of COPD Severity Treatment
More informationFact. Objectives 1/6/2016. Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD)
Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD) Jin S. Oh, PharmD Larkin Community Hospital January 10, 2016 Fact COPD is the third leading cause of death in the United
More informationChanging Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?
New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? Conflict of Interest Statement 2018 Speakers Bureau Astra Zeneca Boehringer Ingelheim Genentech Sunovion Ron Balkissoon MD DIH
More informationCOPD. Helen Suen & Lexi Smith
COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full
More informationWhat is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationCourse Handouts & Disclosure
COPD: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources Hospice Education Network Course Handouts & Disclosure To download presentation
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationCOPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS
IN THE NAME OF GOD COPD Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS Definition of COPD* COPD is a preventable and treatable chronic lung disease characterized by airflow limitation that is not fully
More informationAsthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
More informationThree better than 1 or 2?
Three better than 1 or 2? DISCLOSURE Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance of NS. (DEANS). DEU prepares Drug Evaluation Reports for the Atlantic
More informationAsthma ASTHMA. Current Strategies for Asthma and COPD
Current Strategies for Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor of Medicine Chair, Department of Medicine University of California San Francisco (UCSF) San Francisco,
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationPrimary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD
Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More information9/22/2015 CONFLICT OF INTEREST OBJECTIVES. Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR
Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST
More informationUnderstanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR
Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST
More informationReferring for specialist respiratory input. Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL
Referring for specialist respiratory input Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL Respiratory Specialist- who? GPSI Community Team Secondary Care Respiratory physician and
More informationPharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08
Pharmacological Management of Obstructive Airways in Humans Introduction to Scientific Research Submitted: 12/4/08 Introduction: Obstructive airways can be characterized as inflammation or structural changes
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationTake My Breath Away: COPD Update. Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care
Take My Breath Away: Update Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care Objectives 1. Recognize clinical signs and symptoms associated with chronic bronchitis and emphysema. 2. Describe
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More informationAdvances in Chronic Obstructive Pulmonary Disease
Advances in Chronic Obstructive Pulmonary Disease By Dave C. Todd, MD; and Darcy D. Marciniuk, MD, FRCPC The case of Nina Nina, 64, presents to the clinic with a three- to fouryear history of progressive,
More informationAirway Vista Background
Airway Vista 2013 Chronic Obstructive Airway Diseases Symposium Asan Medical Center, Seoul, South Korea When Should Macrolide Antibiotics be Prescribed to Prevent COPD Exacerbations in Usual Clinical Practice?
More informationPulmonary and Critical Care Year in Review
Pulmonary and Critical Care Year in Review Heath E Latham, MD Assistant Professor University of Kansas Dept of Internal Medicine Division of Pulmonary and Critical Care None Disclosure Lung Cancer Screening
More informationAmerican Thoracic Society (ATS) Perspective
National Surveillance System for Chronic Lung Disease (CLD): American Thoracic Society (ATS) Perspective Gerard J. Criner, M.D. Chronic Obstructive Pulmonary Disease (COPD) l Definition: Group of chronic
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationPulmonary Year in Review
Pulmonary Year in Review Rachel Givelber, MD University of Pittsburgh SOM Pulmonary, Allergy, Critical Care and Sleep Medicine Rachel Givelber, MD Assistant Professor of Medicine PACCM, UPSOM Disclosures
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationChronic Obstructive Pulmonary Disease (COPD).
Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationManagement of Acute Exacerbations of COPD
MiCMRC Educational Webinar Management of Acute Exacerbations of COPD August 22, 2018 MiCMRC Educational Webinar Management of Acute Exacerbations of COPD Expert Presenter: Catherine A. Meldrum PhD RN MS
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationDebating the use of inhaled corticosteroids in the treatment of COPD. COPD Epidemiology. A quick patient case. Risk Factors for COPD 1,2
Debating the use of inhaled corticosteroids in the treatment of COPD Suzanne G. Bollmeier Pharm.D., BCPS, AE-C Associate Professor, St. Louis College of Pharmacy ACPE Guidelines on Non- Commercialism o
More informationPulmonary Rehabilitation in Chronic Lung Disease; Components and Organization. Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept.
Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept. Plan Chronic Respiratory Disease Definition Factors Contributing
More informationClass Update: Asthma / COPD Medications
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationExacerbations of COPD. Dr J Cullen
Exacerbations of COPD Dr J Cullen Definition An AECOPD is a sustained worsening of the patient s clinical condition from their stable state that is beyond their usual day-to-day variation is acute in onset
More informationChronic Obstructive Pulmonary Disease (COPD) Copyright 2014 by Mosby, an imprint of Elsevier Inc.
Chronic Obstructive Pulmonary Disease () 8.18.18 Copyright 2014 by Mosby, an imprint of Elsevier Inc. Description Airflow limitation not fully reversible progressive Abnormal inflammatory response of lungs
More informationMichelle Zeidler, MD, MS
7/1/18 Chronic Obstructive Pulmonary Disease: Optimizing Outpatient Care & Reducing Exacerbations Michelle Zeidler, MD, MS Professor of Medicine, Pulmonary, Critical Care Medicine & Sleep Medicine, VA
More informationWhat is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018
What is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018 No disclosures Disclosures objectives How to diagnose & Assess severity Treatment: Pharmacologic Non-Pharmacologic Maintenance
More informationCOPD exacerbation. Chiara Maruggi, PGY2
COPD exacerbation Chiara Maruggi, PGY2 Learning objectives At the end of this lecture students will be able to: 1) Critically assess patients for COPD and design a management plan. 2) Develop a step-wise
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationClinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms
Clinical Guideline Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,
More informationDr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher
Professor Richard Beasley University of Otago Director Medical Research Institute of New Zealand Wellington Dr Sarah Mooney Physiotherapy Advanced Clinician Counties Manukau Health NZ Respiratory and Sleep
More informationThe impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease
The impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease Dr. Lo Iek Long Department of Respiratory Medicine C.H.C.S.J. Chronic Obstructive Pulmonary Disease (COPD)
More informationBridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide
Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide Altarum Bridges to Excellence 3520 Green Court, Suite 300 Ann Arbor, MI 48105 bte@altarum.org www.bridgestoexcellence.org
More informationWhat is this patient s diagnosis?
Asthma and COPD KANTA VELAMURI, MD ASSOCIATE PROFESSOR OF MEDICINE PULMONARY, CRITICAL CARE AND SLEEP MEDICINE SECTION MICHAEL E. DEBAKEY VA MEDICAL CENTER BAYLOR COLLEGE OF MEDICINE Disclosures None Case
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP230 Section: Medical Benefit Policy Subject: Outpatient Pulmonary Rehabilitation I. Policy: Outpatient Pulmonary Rehabilitation II. Purpose/Objective: To provide
More information